Key Highlights
- LITE reached a record peak of $808.80 during Thursday’s session, settling at $777.17
- Recent S&P 500 addition triggered index fund and ETF purchases
- Wall Street analysts increased price targets, with some adjustments reaching 66%
- Q2 results surpassed expectations with EPS of $1.67 compared to anticipated $1.41, while revenue climbed 65.5% annually
- Company revealed plans for a 240,000 square foot North Carolina manufacturing site producing AI datacenter lasers, counting Nvidia among its customers
Lumentum (LITE) shares reached an unprecedented $808.80 peak during Thursday trading before moderating to $777.17 at market close. During premarket hours on March 26, shares declined 3.49% to $750.
The remarkable ascent stems from converging catalysts including Wall Street optimism, major index membership, robust financial performance, and a significant expansion announcement.
The company unveiled intentions to establish a laser manufacturing operation in Greensboro, North Carolina. The 240,000 square foot property, purchased from semiconductor manufacturer Qorvo (QRVO), will manufacture InP-based optical components, featuring continuous wave and ultra-high-power laser systems.
Nvidia (NVDA) has committed to purchasing products from this facility. Manufacturing operations are scheduled to begin scaling in mid-2028.
Lumentum plans to allocate several hundred million dollars to the site over coming years. The company commits to maintaining and generating more than 400 domestic manufacturing positions.
CEO Michael Hurlston stated: “Our customers are building the infrastructure that will define the next era of computing. Adding this new InP manufacturing facility significantly expands our capacity, deepens our strategic partnerships, and ensures we can deliver the performance, reliability, and scale required for the AI revolution.”
Wall Street Target Revisions and Index Membership
Multiple analyst firms revised their outlook on LITE, contributing to the upward momentum. B. Riley elevated the stock from neutral to buy while boosting its target from $147 to $526. JPMorgan established a $565 target with an overweight designation. Citigroup moved to $560 with a buy recommendation. UBS adjusted its target upward from $215 to $455, maintaining a neutral stance. Morgan Stanley increased its projection to $595 while keeping an equal weight designation.
The consensus analyst price target currently stands at $575.06, with two strong buy recommendations, eleven buy ratings, and six hold positions.
Lumentum gained admission to the S&P 500 recently, a development that generally triggers mechanical purchasing from passive index funds and exchange-traded products. This structural demand likely amplified the upward movement.
Financial Performance and Valuation Considerations
During its latest reporting period, Lumentum delivered EPS of $1.67, surpassing the $1.41 analyst consensus. Revenue totaled $665.50 million, representing a 65.5% year-over-year increase and exceeding the $646.74 million projection. Management issued Q3 2026 EPS guidance ranging from $2.15 to $2.35.
Some metrics warrant attention. The stock carries a P/E ratio of 238, representing a premium valuation by most standards. Company insiders have reduced holdings — CFO Wajid Ali divested 5,302 shares in late February at approximately $691.13 per share, while insiders collectively sold 65,775 shares during the past 90 days.
Institutional ownership comprises 94.05% of outstanding shares. Vanguard, Arrowstreet Capital, and Geode Capital each expanded their stakes in recent quarters.
The 50-day moving average registers at $567.66, while the 200-day stands at $363.11 — both significantly below current price levels.
